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Background: Varicella and herpes zoster are both caused by varicella zoster virus (VZV) infection or reactivation and
may lead to complications associated with a (severe) societal burden. Because the epidemiology of VZV-related
diseases in the Netherlands remains largely unknown or incomplete, the main objective of this study was to study
the primary care incidence, associated complications and health care resource use.
Methods: We investigated the incidence of VZV complications in the Dutch general practitioner (GP) practices and
pharmacies in a retrospective population-based cohort study (2004–2008) based on longitudinal GP data including
free text fields, hospital referral and discharge letters from approximately 165,000 patients.
Results: The average annual incidence of varicella GP-consultations was 51.5 per 10,000 (95% CI 44.4-58.7) overall;
465.5 per 10,000 for 0–1 year-olds; 610.8 per 10,000 for 1–4 year-olds; 153.5 per 10,000 for 5–9 year-olds; 8,3 per
10,000 for >10 year olds. When only ICPC coded diagnoses were analyzed the incidence was 27% lower. The
proportion of complications among varicella patients was 34.9%. Most frequently complications were upper
respiratory tract infections. Almost half of the varicella patients received medication. The referral rate based on GP
consultations was 1.7%. The average annual incidence of herpes zoster GP-consultations was 47.5 per 10,000 (95%
CI 40.6-54.4). The incidence increased with age; 32.8 per 10,000 for <60 year-olds; 93.1 per 10,000 for 60–64
year-olds and 113.2 per 10,000 for >65 year olds. When estimating herpes zoster incidence only on ICPC coded
information, the incidence was 28% lower. The complication rate of herpes zoster was 32.9%. Post herpetic
neuralgia was seen most often. Of patients diagnosed with herpes zoster 67.8% received medication. The referral
rate based on GP consultations was 3.5%.
Conclusions: For varicella the highest incidence of GP-consultations was found in 1–4 year-olds, for herpes zoster
in the >65 years olds. The occurrence of complications was not age-dependent but varies per complication. When
estimating incidence of VZV-related diseases in primary care, based on diagnostic codes only, one should be aware
of a gross underestimation of the incidence. Our analysis may have important implications for the outcomes of
upcoming cost-effectiveness analyses on VZV vaccination.
Keywords: Varicella, Herpes zoster, EpidemiologyBackground
Varicella zoster virus (VZV) infection causes two dis-
eases; varicella and herpes zoster. The epidemiology and
burden of both VZV-related diseases and associated
complications in the Netherlands is largely unknown or
incomplete.* Correspondence: m.j.postma@rug.nl
1Department of Pharmacy, Unit of PharmacoEpidemiology &
PharmacoEconomics, University of Groningen, Antonius Deusinglaan 1,
Groningen 9713 AV, The Netherlands
Full list of author information is available at the end of the article
© 2012 Pierik et al.; licensee BioMed Central L
Commons Attribution License (http://creativec
reproduction in any medium, provided the orThe primary disease burden of VZV infection is vari-
cella. Varicella is a common viral childhood disease
affecting nearly the entire birth cohort. In a non-
vaccinated population such as the Netherlands the risk
of acquiring a primary VZV infection is over 97% and
most people contract varicella before the age of five [1].
While varicella is usually self-limiting, a case of varicella
can potentially develop serious complications and may
lead to hospitalization and even death [2-4]. Following
primary infection, VZV becomes latent in the dorsal root
ganglia and may reactivate later in life resulting intd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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vesicular rash, accompanied by it’s most common com-
plication post-herpetic neuralgia (PHN) [6]. But herpes
zoster can give rise to other complications, many of
which have unusual presentations and serious or even
life-threatening sequelae [7,8].
VZV-related incidences and complications have been
estimated in different national and international studies
[1,2,9-13]. Most of these studies were limited to
hospitalization records associated with varicella or
herpes zoster as a measure of disease complications.
These restrictions do not allow for a full analysis of the
complications associated with VZV as most patients are
likely to visit only a general practitioner (GP). Therefore,
morbidity presented in the general daily practice might
be a better indicator of VZV morbidity in the general
population [14]. In particular, in the Netherlands GPs
are usually the first point of contact with the Dutch
healthcare system and basically all non-institutionalized
people are registered at a GP.
In the Netherlands, the VZV-incidence presented in
the primary care are coded according to the Inter-
national Classification of Primary Care (ICPC). The
Netherlands Institute of Health Services Research
(NIVEL) collects weekly these ICPC-coded anonymized
patient information on VZV-infection. However, this
method comprises a risk of potential underdetection of
the disease and related complications because it excludes
the analysis of free text fields which allow for a more
elaborate analysis of non-coded information.
Prevention by vaccination could be an optimal ap-
proach in the management of VZV disease. At this mo-
ment decisions about introducing VZV vaccination in
routine immunization programme in the Netherlands
have not been made, assumed due to the lack on epide-
miologic information and perception that varicella in
young children may generally not be a serious disease.
Given the lack of data, more insights into the epidemi-
ology of VZV infections and into the disease burden, are
needed. In particular in the Netherlands, the Dutch
Health Council stated that more epidemiological infor-
mation is required to decide on the introduction of VZV
vaccination in the NIP [15]. We studied the primary care
incidence of varicella and herpes zoster, their associated
complications, health care resource use, in a GP’s re-
search database which also included free text fields.
Methods
Setting
Primary health care use was estimated from the Zorg-
groep Almere (ZGA). Data available through ZGA are
based on electronic medical records from 22 general
practices, spread throughout Almere, one of the largest
Dutch cities (approximately 185,000 inhabitants). ZGAdatabase contains information on approximately 167,000
inhabitants. Data include longitudinal information on
patient’s characteristics, such as age, sex, as well as med-
ical information, on consultations, prescriptions, refer-
rals, laboratory values and diagnoses. GPs participating
in ZGA are instructed to use ICPC-1 codes for every pa-
tient contact. Furthermore, summaries of the hospital
discharge letters and information from specialists are
entered in a free text format. Information on drug pre-
scription comprises brand name, quantity, strength, indi-
cation, prescribed daily dose, dispensing date and the
Anatomical Therapeutical Chemical (ATC) classification
code.Study design
The design of the study was a longitudinal retrospective
population-based cohort study. This study was restricted
to the analysis of all persons with permanent registration
status with one of the GPs who contributed to the data-
base of Zorggroep Almere. In particular, the database
comprised 164,631 in 2004 and increased to 166,616
persons in 2008. Based on ICPC-codes A72 and S70, in-
cluding free text in the notes of the electronic record,
probable cases of VZV-infections from January 1st, 2004
to December 31st, 2008 were identified. Note, anonymo-
nized patient data was provided by ZGA, therefore,
according to Dutch regulations no ethical approval was
required for this study [16].Patient identification - case definition
Using a computerized algorithm, we included patients
with an ICPC-code for varicella (A72). In addition, to
avoid potential underdetection of varicella, we included
all patients with suspected varicella, using a sensitive
search algorithm to the notes section of each electronic
medical record. Of all varicella suspected patients with
an insect bite or sting (ICPC-code S12) were excluded
from our analyses. Herpes zoster patients were included
according to the ICPC-code S70 or/and if herpes zoster
was suspected. Cases of a previous diagnosed and on-
going treatment for PHN (coded with ICPC-code
S70.02) were excluded. Both searches included possible
misspellings of varicella and herpes zoster. The compu-
terized medical records of all potential cases were
reviewed carefully. We included cases when the records
stated an infection with varicella or herpes zoster. For
each case, the date of the first VZV-related consultation
was taken as index date. For a subgroup of patients the
index date was restricted to the month of the GP visit.
Considering the feasibility of the analyses we set the date
for this group on the first day of the month. Varicella
and herpes zoster monthly incidence was extracted from
the dataset.
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First, based on a literature search a list of potential med-
ical and lay names for the retrieval of potential cases of
VZV-related complications and symptoms from the free
text search in the electronic patient records was gener-
ated [17-20]. This list was compiled by sending the list
of selected complications to a small group of Dutch
experts consisting of two GPs and two paediatric infec-
tious disease specialists.
In order to identify VZV-related complications in the
GP practice, we performed an extended computerized
database search within the free text or on ICPC-code of
the medical records using the Dutch version of the words
as shown in Additional file 1 (varicella) and Additional file
2 (herpes zoster). Varicella-related complications and
symptoms were divided in groups as follow: upper respira-
tory tract; ENT (ear, nose and throat) and eye complica-
tions; lower respiratory tract complications; skin
infectious/cutaneous complications; neurologic complica-
tions; gastrointestinal tract complications; haematological
complications; complications due to (systemic) bacterial
infections; and symptoms as a more general category.
Accordingly, reported herpes zoster-related complica-
tions and symptoms were categorized into the following
ten groups: upper respiratory tract; ENT complications;
eye complications; lower respiratory tract complications;
skin infectious/cutaneous complications; PHN; neuro-
logic complications other than PHN; gastrointestinal
tract complications; haematological complications; com-
plications due to (systemic) bacterial infections; and
again symptoms as a more general group. VZV-related
complications were defined as those occurring within
30 days before or after consultation for VZV infections,
with the exception of post-herpetic neuralgia (PHN), be-
cause some cases of PHN may last for several months or
years [20]. If the cases visited the GP more than once for
the same indication we counted the complication once.
All referrals and discharge letters in the primary care
database were reviewed in order to identify VZV-related
complications in hospital care among the previously
selected VZV-patients between 21 days before and 40 days
after the index date. Note, that data was only derived in a
primary care setting. We identified all the patients with an
ICPC-code for varicella (A72) or herpes zoster (S70) and
free text (chickenpox; varicella) or (shingles; herpes zoster)
in their referral or discharge letter. To avoid underestima-
tion, all referrals and discharge letters of VZV-cases were
reviewed on highly plausible associated complications, for
example post-viral cerebellitis. Referral rates were calcu-
lated based on GP consultations.
Treatment of VZV-infections
VZV-related medication use was identified by an
extended computerized database search on ATC codesas shown in Additional file 3 . Medication use was
selected 21 days before and after the index date and was
analyzed on relevance. Only medication related to vari-
cella, herpes zoster or VZV-related complications were
included.
Medications were divided in ten groups based on their
ATC code: anaesthetics; analgesics; antivirals (local);
antivirals (systemic); antibacterials (local); antibacterials
(systemic); corticosteroids; antipruritics and emollientia;
immunoglobulins; and vaccines (Additional file 3).
Analysis
Data has been stored and analyzed using Microsoft Ac-
cess, Microsoft Excel and PASW Statistics 18. Because
the age distribution in our database slightly differed
from the age distribution of the Dutch population we
determined standardized incidence estimates of varicella
and herpes zoster when extrapolating our results to the
Dutch population. These extrapolated results were
established using data from the Central Bureau for Sta-
tistics (CBS, www.cbs.nl, 2004–2008). The age groups
for varicella incidence and associated complications were
defined as 0; 1–4; 5–9 and further 5-year-classes till
20 years and above. For herpes zoster this age group was
0–59; 60–64 and >65-years olds. For calculation of inci-
dence rates 95% upper and lower confidence intervals
(CI) were used.
To increase plausibility of causal associations between
a complication and a VZV infection the complications
rates were corrected for a baseline rate. This baseline
rate was determined as the background complication
rate for the general population in these age classes. Ver-
ruca was selected because verruca is, like herpes zoster
and varicella, a viral-induced skin disease generally oc-
curring in the same age classes. Verruca is not asso-
ciated with (severe) VZV-induced complications and is
therefore assumed to be comparable to the general
population. The background complication rate was
established by completing the same analysis for verruca
(ICPC–code S03). The corrected rates were used to dif-
ferentiate in complication rates between healthy indivi-
duals (i.e. verruca patients) and patients (i.e. varicella or
HZ patients). Corresponding 95% CI were obtained
using the Taylor series linearization method [21]. Statis-
tical significance was defined as p< 0.05.
After this correction for the baseline occurrence of the
potential complications certain complications as appen-
dicitis, trombocytopenia, vertigo were excluded as hav-
ing a causal relationship (p< 0.05) with VZV infection.
Complications, known as typical VZV associated compli-
cations, like cerebellitis, osteomyelitis, meningitis and
sepsis were included. To increase plausibility of causal
associations of medication use, also medication use was
corrected for a baseline rate of verruca. In general the
Figure 1 Average age-specific incidence of varicella infection
from 2004 to 2008.
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ability of complications was calculated over the years,
because of the low sample size of some complications.
Results
In the total cohort analyzed, including 164,631 (2004) to
166,616 (2008) persons; 5,273 patients had a GP consult-
ation for varicella during the period 2004–2008 (Table 1).
During the same period 3,371 patients had a GP consult-
ation for herpes zoster.
Varicella
Incidence of varicella GP consultations
The average of the annual overall incidence of varicella
GP consultations in the Netherlands (Figure 1 and
Table 1), corrected for age distribution of the population,
was 51.5 per 10,000 (95% CI 44.4-58.7); 465.5 per 10,000
for 0–1 year-olds; 610.8 per 10,000 for 1–4 year-olds;
153.5 per 10,000 for 5–9 year-olds; 18.0 per 10,000 for
10–14 year-olds; 9.2 per 10,000 for 14–19 year-olds and
7.2 per 10,000 for >20 year-olds (ICPC-coded and free
text information). The median age at GP consultations
was 3.67 years (IQR: 1.95-5.41). When only ICPC-coded
diagnoses were analyzed; the annual overall incidence of
GP consultations was 37.7 per 10,000. Of these cases
1.6% was false-positive. The annual age-specific inci-
dence of varicella from 2004 to 2008 shows epidemio-
logical fluctuations (Figure 2). The overall standardized
annual incidence ranged from 43.8 (2005) to 58.3 per
10,000 (2007) population. As well as the absolute num-
ber of varicella cases ranged from 71,375 (2005) to
95,289 (2007). In addition, the incidence of varicella
shows a seasonal pattern. In particular, the epidemic sea-
son for varicella is late winter/early spring, particularly
from February till May (Figure 3).
Varicella-related complications and symptoms in primary
care
During the studied period 5,273 patients with varicella
required a GP consultation, of whom 3,901 (74.0%) had
any registrated VZV-related complication or symptom.
The distinction between the definition of symptoms andTable 1 Incidence and number of VZV cases per year
Varicella Herpes zoster
Total patients
(n) registred at
GP
cases
(n)
incidence
per 10,000
population
cases
(n)
Incidence
per 10,000
population
2004 164,631 1,018 49.88 619 45.03
2005 166,576 893 43.77 662 46.99
2006 166,344 1,018 49.20 652 44.67
2007 166,141 1,199 58.26 700 49.67
2008 166,616 1,145 56.60 738 51.10complications is addressed in Table 2. Most prevalent
symptoms were fever (39.9%), pruritis (27.8%) and
coughing (10.5%). (Table 2; note, rates were corrected
for the incidence of complications found in verruca
patients) Among all varicella patients, 34.9% (n = 1841)
consulted a GP for a complication. Upper respiratoryFigure 2 Annual age-specific incidence of varicella infection
from 2004 to 2008.
Figure 3 Seasonal distribution of varicella infections by month.
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the cases. Upper respiratory tract infection (13.0%) and
otitis media (7.5%) were the most frequent complica-
tions. Lower respiratory tract complications occurred in
3.8% of the cases of which 0.6% had pneumonia. Skin
infections and cutaneous complications due to varicella
occurred in 5.6% of the cases; most frequent complica-
tion was impetigo (3.0%). Neurologic complications oc-
curred in 0.9% of the cases, most commonly convulsions
(0.7%), but also more serious complications as encephal-
itis and meningitis were registrated (encephalitis once
and meningitis three times during the study period). Ser-
ious complications were also seen due to systemic bac-
terial infections in a small group (n = 8). The occurrence
of complications was not age-dependent but varies per
complication. Complications as otitis media, bronchitis,
convulsions were seen more often in children <4 years
of age and pharyngitis, neuralgia and pneumonia more
often in >20 year-olds (Table 2; corrected rates). None
of the patients died due to varicella infection.Varicella incidence and complications requiring hospital
care
The incidence of consultation for varicella in hospital
care, corrected for age distribution of the population,
was 0.86 per 10,000. The overall referral rate based on
GP consultations among all varicella cases was 1.7%. For
varicella 89 cases were referred to the hospital for com-
plications associated with VZV infection. The median
age of the cases was 2.28 years (IQR: 0.96-4.01). Most
cases (69%) visited a pediatrician and 19% of the cases
went to the emergency care. Most common complica-
tions in hospital care were dehydration (14.6%); skin
super infections (18%) and pneumonia (12.4%) (Table 3).Treatment of varicella infections
Approximately 47.7% of the patients received medication
for varicella or associated complication (Table 4). For vari-
cella less than 1% of the cases received antiviral therapy
while 11.2% of the cases used antibacterials. Most com-
mon therapy for varicella was based avoiding itching.
Hence, 13.5% of the cases received aneasthetics and 11.3%
antipruritics and emollientia. VZV immunoglobulins were
prescribed in three cases. Some medication gave a nega-
tive corrected rate, analgesics and local antivirals, as the
baseline rate was higher then the percentage of use among
varicella patients, suggesting no association with varicella.
Herpes zoster
Incidence of herpes zoster GP consultations
The average annual number of herpes zoster GP consul-
tations in the Netherlands, corrected for age distribution
of the population, was 47.5 per 10,000 (95% CI 40.6-
54.4). The incidence increased with age; 32.8 per 10,000
for <60 year-olds; 93.1 per 10,000 for 60–64 year-olds
and 113.2 per 10,000 for >65 year olds (ICPC-coded
and free text information) (Figure 4). The median age
was 48.51 years (IQR: 29.37-62.41). The incidence ran-
ged from 44.7 (2006) to 51.1 (2008) per 10,000 popula-
tion, annually (Figure 5). Furthermore, the absolute
number of herpes zoster cases raged from 72,969 (2006)
to 83,828 (2008). If the herpes zoster incidence was esti-
mated on ICPC-code only, the incidence was 34.0 per
10,000.
Herpes zoster-related complications and symptoms
Of the 3,371 herpes zoster cases identified, 2,155 (63.9%)
had any complication or symptom. Among the zoster
cases, we found a complication rate of 32.9% (n = 1,108).
The distinction between the definition of symptoms and
complications is addressed in Table 5. Common symp-
toms were pruritis (22.6%), fever (12.4%) and skin rash
(11.0%).
Neurological complications were found in 13.5% of the
cases. Post-herpetic neuralgia (5.8%) and trigeminal
neuralgia (2.2%) were the most frequent neurological
complications. Fifteen percent of the cases had an upper
respiratory tract or ENT complication. Complications
associated with herpes zoster were ocular complications
(4.4%) and lower respiratory tract infections (1.9%). Ap-
proximately 6.9% of the cases develop cutaneous compli-
cations, most common impetigo (2.7%). Serious systemic
bacterial complications as sepsis and pyogen arthritis
were found in 0.1% of the cases. Three cases died within
one month after herpes zoster consultation (Table 5).
Herpes zoster incidence and complications in hospital care
There were 119 herpes zoster related hospital referrals,
i.e. 1.55 per 10,000. The overall referral rate based on
Table 2 Varicella-related complication rates in Primary Care
Complication rates
all ages
Complication rates (%)
per age group
Corrected rates (%)
(n = 5,273) (n) (%) (95% CI) 0-4 5-9 10-19 >20 All ages (95% CI) <10 (95% CI)
Upper respiratory tract. ENT complications
Conjunctivitis 162 3.07 (2.64-3.57) 3.5 1.9 0.6 2.9 2.08* (1.58-2.57) 1.98* (1.38-2.58)
Otitis media 619 11.74 (10.90-12.64) 13.7 8.7 3.6 4.6 7.49* (6.56-8.42) 7.48* (6.32-8.64)
Upper respiratory tract infection 942 17.86 (16.85-18.92) 21.0 10.3 3.0 13.5 13.03* (11.93-14.12) 12.82* (11.50-14.15)
Lymphadenitis 32 0.61 (0.43-0.86) 0.6 0.9 0.0 0.2 0.51* (0.29-0.72) 0.57* (0.32-0.82)
Tonsillitis 219 4.15 (3.65-4.73) 4.4 4.2 3.0 2.2 2.84* (2.27-3.41) 2.26* (1.53-2.99)
Pharyngitis 46 0.87 (0.65-1.16) 0.8 0.8 1.2 1.9 0.32* (0.04-0.60) 0.32 (0.00-0.64)
Sum of complications 2.020 38.31 (37.01-39.63) 44 26.8 11.4 25.3 26.27 25.43
Total number of patientsa 1.516 28.75 (27.54-29.99)
Lower respiratory tract complications
Pneunomia 41 0.78 (0.57-1.05) 0.6 1.1 0.6 1.9 0.63* (0.39-0.88) 0.49* (0.23-0.76)
Bronchitis 163 3.09 (2.66-3.59) 3.7 1.8 1.2 1.4 2.26* (1.77-2.75) 2.41* (1.83-3.00)
Sum of complications 204 3.87 (3.38-4.42) 4.3 2.9 1.8 3.3 2.89 2.90
Total number of patientsa 199 3.77 (3.29-4.32)
Skin infectious/cutaneous complications
Pyoderma 7 0.13 (0.06-0.27) 0.1 0.0 0.0 0.5 0.05 (−0.06-0.16) 0.11* (0.01-0.20)
Abscess 19 0.36 (0.23-0.56) 0.3 0.4 0.6 0.7 0.04 (−0.15-0.23) 0.20* (0.01-0.39)
Skin infection 37 0.70 (0.51-0.97) 0.7 0.8 0.6 0.7 0.52* (0.28-0.76) 0.63* (0.38-0.88)
Scar Tissue 53 1.01 (0.77-1.31) 0.8 0.9 2.4 2.6 0.21 (−0.10-0.51) 0.39* (0.07-0.71)
Impetigo 196 3.72 (3.24-4.26) 4.1 3.4 2.4 1.4 3.04* (2.51-3.57) 2.49* (1.82-3.15)
Sum of complications 312 5.92 (5.31-6.59) 6.0 5.5 6.0 5.9 3.86 3.82
Total number of patientsa 297 5.63 (5.04-6.29)
Neurologic complications
Neuralgia 2 0.04 (0.01-0.14) 0.0 0.0 0.0 0.5 0.02 (−0.03-0.08) 0.00
Meningitis 3 0.06 (0.02-0.17) 0.1 0.0 0.0 0.2 0.05 (−0.02-0.12) 0.04 (−0.02-0.10)
Encephalitis 1 0.02 (0.00-0.11) 0.0 0.1 0.0 0.0 0.02 (−0.02-0.06) 0.02 (−0.02-0.06)
Convulsion 37 0.70 (0.51-0.97) 0.9 0.3 0.0 0.0 0.69* (0.46-0.91) 0.77* (0.51-1.02)
Ataxia (Cerebellitis) 1 0.02 (0.00-0.11) 0.0 0.0 0.0 0.0 0.02 (−0.02-0.06) 0.02 (−0.02-0.06)
Movement and stability dysfunction 1 0.02 (0.00-0.11) 0.0 0.0 0.0 0.2 0.02 (−0.02-0.06) 0.00 (0.00-0.00)
Facial Palsy 2 0.04 (0.01-0.14) 0.03 0.0 0.0 0.2 0.04 (−0.01-0.09) 0.02 (−0.02-0.06)
Coma 1 0.02 (0.00-0.11) 0.0 0.0 0.6 0.0 0.02 (−0.02-0.06) 0.00 (0.00-0.00)
Sum of complications 48 0.91 (0.69-1.20) 1.0 0.4 0.6 1.1 0.88 0.87
Total number of patientsa 48 0.91 (0.69-1.20)
Gastrointestinal tract complications
Stomatitis 16 0.30 (0.19-0.49) 0.4 0.2 0.0 0.2 0.27* (0.12-0.43) 0.27* (0.10-0.45)
Gastroenteritis 125 2.37 (1.99-2.82) 2.8 1.5 0.0 1.7 1.46* (1.84-2.67) 1.60* (1.07-2.13)
Sum of complications 141 2.67 (2.27-3.15) 3.2 1.7 0 1.9 1.73 1.87
Total number of patientsa 139 2.64 (2.24-3.10)
Complications due to (systemic) bacterial infections
Sepsis 4 0.08 (0.03-0.19) 0.1 0.1 0.0 0.0 0.07 (−0.01-0.14) 0.09 (0.00-0.17)
Osteomyelitis 1 0.02 (0.00-0.11) 0.03 0.0 0.0 0.0 0.02 (−0.02-0.06) 0.02 (−0.02-0.06)
Pyogen arthritis 3 0.06 (0.02-0.17) 0.03 0.0 0.0 0.5 0.06 (−0.01-0.12) 0.02 (−0.02-0.06)
Sum of complications 8 0.15 (0.08-0.30) 0.2 0.1 0.0 0.5 0.15 0.13
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Table 2 Varicella-related complication rates in Primary Care (Continued)
Total number of patientsa 8 0.15 (0.08-0.30)
Symptoms
Mouth blisters 55 1.04 (0.80-1.36) 0.9 1.1 1.8 1.4 0.98* (0.70-1.26) 0.86* (0.56-1.16)
Coughing 757 14.36 (13.44-15.33) 17.0 8.7 1.8 9.4 10.50* (9.50-11.50) 10.83* (9.63-12.03)
Snivelling 237 4.49 (3.97-5.09) 6.1 0.7 0.6 0.5 4.18* (3.62-4.75) 4.45* (3.79-5.11)
Fever 2.550 48.36 (47.01-49.71) 51.5 40.2 37.0 44.0 39.91* (38.48-41.34) 37.96* (36.25-39.68)
Fatigue 401 7.60 (6.92-8.35) 9.3 3.9 3.0 3.4 6.02* (5.27-6.76) 7.02* (6.17-7.86)
Emesis/Vomiting 417 7.91 (7.21-8.67) 9.1 5.1 6.1 4.3 6.47* (5.72-7.23) 6.34* (5.45-7.24)
Problems Eating/drinking 664 12.59 (11.72-13.52) 15.2 7.1 6.1 4.8 10.73* (9.81-11.65) 11.75* (10.70-12.81)
Pruritis/Itching 1.845 34.99 (33.71-36.29) 32.1 40.0 44.2 45.2 27.82* (26.46-29.17) 28.11* (26.59-29.63)
Skin rash/Exanthema 439 8.33 (7.61-9.10) 8.2 6.8 12.7 11.3 7.46* (6.69-8.22) 7.02* (6.19-7.84)
Dehydration/Diarreah 433 8.21 (7.50-8.98) 10.0 4.5 3.0 2.9 6.72* (5.95-7.49) 7.04* (6.13-7.94)
aThe total number of patients may be less than the total sum of complications because some patients had more than one complication in this group.
* = p< 0.05.
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age of the cases was 52.8 years (IQR: 40.72-66.91). More
than 35% of the cases were seen by a dermatologist; 23%
by an ophthalmologist and 16% by a neurologist. Most
common complications were herpes zoster dermatomal
rash (37.8%); herpes zoster ophthalmicus (27.7%) and
neurological pain (8.4%) (Table 3).
Treatment of herpes zoster infections
Approximately 67.8% of the herpes zoster cases received
medication (Table 4). Almost one-quarter of the patients
received antiviral therapy, most systemic antivirals
(22.0%). More than 15% of the cases received antibacter-
ials, most often local antibacterials (10.3%). Of the
patients, 11.5% received antipruritics and emollientia
and 6.4% used aneasthetics. Analgesics were used in
13.5% of the cases.
Discussion
We used data from a research database from the munici-
pality of Almere, combining GP, hospital data and phar-
macy data to analyze the epidemiologic characteristics
and disease burden of varicella and herpes zoster in the
Netherlands. This study shows that the incidence of GP-
diagnosed VZV infections is much higher than expected
based on ICPC-codes solely. Because the use of both,
coded and non-coded information, the incidences found
in present study provide updated data on the number of
people with VZV complaints that prompt patients to
seek medical care.
Varicella
To our knowledge, the current study is the first varicella
study based on ICPC-coded and non-coded information.
Our data confirms the burden of varicella as a common
disease which affects a large proportion of thepopulation each year, as demonstrated by the high over-
all standardized annual GP-incidence rate of 51.5 per
10,000. When including free text in this analysis the in-
cidence of varicella is over twice as high when compared
to the national registration system. When the analyses
were restricted to coded information the national regis-
tration system registrated an incidence of 22.2 per
10,000 based on coded information for varicella (2004–
2008) [22] whereas, the incidence determined in ZGA
was higher, namely 37.7 per 10,000 over the same
period. Currently Dutch epidemiological data may not
accurately reflect the true burden of varicella due to
under-reporting to statutory notification systems. Under-
estimation of national registration is not unusual, it is
shown before in the Netherlands and abroad [6,23,24]
for VZV infections and other diseases [25]. Our overall
incidence of VZV-related GP consultations is compar-
able to England and Wales, where the incidence is ap-
proximately 50.7 per 10,000 [26].
Most people in the Netherlands will have contracted
varicella, before the age of five [1]. Our data show a
comparable age-specific disease distribution to a study
about Dutch VZV-seroprevalence, where 93% of the
people already contract varicella before the age of five
[1]. Compared to other countries the mean age of infec-
tion in the Netherlands is rather low [27]. Yet, there are
studies that show a decrease in the peak age of varicella
in England. Between 1983 and 1998 the incidence rates
for varicella fell in children aged 5–14 years old (by
about 50%), but doubled in children aged 0–4 years [28].
Despite public perception of varicella infection being a
harmless childhood disease, different complications can
occur [29]. The most common complications associated
with varicella in primary care are upper respiratory tract
infections, otitis media and impetigo. Complications
were not limited to infections beyond adolescence, as
Table 3 VZV complications in Hospital Care
Varicella (n = 89) n (%) Herpes zoster (n = 119) n (%)
Neurologic complications Neurologic complications
Meningitis 1 (1.1%) Meningitis 1 (0.8%)
Cerebrellitis 1 (1.1%) Cerebellitus 1 (0.8%)
Bells palsy 1 (1.1%) Postherpetic neuralgia 4 (3.4%)
Convulsions 7 (7.9%) Trigeminal neuralgia 3 (2.5%)
Headache 1 (1.1%) Bells palsy 1 (0.8%)
Ataxia 1 (1.1%) Facial palsy 7 (5.9%)
Cutaneous complications Neurological pain 10 (8.4%)
Skin superinfections 16 (18%) Herpes zoster oticus 1 (0.8%)
Cellulitis 2 (2.2%) Ocular complications
Phlegmon 1 (1.1%) Herpes zoster ophthalmicus (not specified) 20 (16.8%)
Abscess 1 (1.1%) Conjunctivitis 3 (2.5%)
Impetigo (secondary) 2 (2.2%) Keratitis 4 (3.4%)
Scar tissue 3 (3.4%) Visus 5 (4.2%)
Complications due to systemic bacterial infections Cutaneous complications
Osteomyelitis 1 (1.1%) Herpes zoster dermatome 45 (37.8%)
Pyogen artritis 1 (1.1%) Cellulitis 1 (0.8%)
Sepsis 1 (1.1%) Pyoderm 1 (0.8%)
Respiratory tract complications Cutaneous pain 1 (0.8%)
Pneumonia 11 (12.4%) Skin superinfections 2 (1.7%)
Bronchitis (acute) 1 (1.1%) Other complications
Upper resperatory tract infection (not specified) 2 (2.2%) Pneumonia 5 (4.2%)
Tonsillitis 2 (2.2%) Thrombocytopenia 1 (0.8%)
Lymphadenitis 3 (3.4%) Sepsis 1 (0.8%)
Pharyngitis 1 (1.1%)
Other complications
Stomatitis 3 (3.4%)
Hemorrhagic varicella 1 (1.1%)
Fever (extremely high temperature) 3 (3.4%)
Dehydration 13 (14.6%)
Thrombocytopenia 1 (1.1%)
Anemia 1 (1.1%)
Extreme varicella (not specified/unknown complications) 5 (5.6%)
* a case can have more than one complication.
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common belief some complications have the tendency to
decrease with age while other complications increase, i.e.
age seems not the only factor that drives complications
associated with VZV. In the majority of cases varicella is
a self-limiting disease and usually no specific treatment
is required. Nevertheless, 34% of the varicella patients
seeking GP consultation develop an associated complica-
tion and nearly half of the patients who consulted the
GP received medication, mostly antibacterials. Based on
the results presented in this study we estimate thatbetween 3 to 8% of all Dutch patients with varicella, de-
pending on age, consult a GP due to a complication.
Our findings are similar to data from Germany [32],
France [33] and the United States of America [34], were
it is estimated that in approximately 2 to 6% of cases
attending a general practice. Furthermore of these vari-
cella patients 1.7% experiences complications severe
enough to seek hospital care. The incidence of hospital
admission was 0.86 per 10,000, which is comparable
with recently published Dutch hospitalization data [23].
Though these percentages are low they portray
Table 4 VZV-related treatment
Varicella Herpes zoster
Medication Prescriptions Varicella cases Corrected Prescriptions HZ cases Corrected
n n (%) (%) n n (%) (%)
Anaesthetics 925 831 (15.8%) 13.5% * 518 364 (10.8%) 6.4%*
Analgesics 124 110 (2.1%) −1.5% 1.097 577 (17.1%) 13.5%*
Antivirals (local) 17 17 (0.3%) −1.2% 67 58 (1.7%) 0.1%
Antivirals (systemic) 24 21 (0.4%) 0.3%* 864 748 (22.2%) 22.0%*
Antibacterials (local) 588 487 (9.2%) 6.7%* 594 453 (13.4%) 10.9%*
Antibacterials (systemic) 678 568 (10.8%) 4.4%* 449 354 (10.5%) 4.5%*
Corticosteroids 394 316 (6.0%) 0.3% 372 316 (9.3%) 0.9%
Antipruritics and emollientia 1.136 1.004 (19.0%) 11.3%* 761 646 (19.2%) 11.5%*
Immunoglobulins 3 3 (0.1%) 0.1% 1 1 (0.03%) 0.03%
Vaccines 0 0 (0.0%) 0.0% 0 0 (0.00%) 0.0%
Total (any medication) 3.889 2.516 (47.7%) 4.723 2.286 (67.8%)
* = p< 0.05.
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fractions of all patients with a varicella infection.
Herpes zoster
While varicella is a common childhood disease, herpes
zoster occurs with increasing frequency with increasingFigure 4 Average age-specific incidence of herpes zoster
infection from 2004 to 2008.age [5]. The incidences found in the present study
increased with age: 32.8 per 10,000 for <60 year-olds,
93.1 per 10,000 for 60-64-year-olds and 113.2 per 10,000
for people above 65-years; with an overall standardized
annual incidence of 47.5 per 10,000 (95% CI 40.6-54.4).
This is comparable with incidences found in United
Kingdom [35] and United States [36] in this period. Our
overall incidence is higher than the Dutch registration of
32.5 per 10,000 (1998–2001) [1] but our incidence based
on coded information only is nearly compatible with
Dutch registry, namely 34.0 per 10,000. This incidence is
similar to a previous Dutch study [6] and data from the
Belgium sentinel system [37]. The incidence of consult-
ation in hospital care is 1.55 per 10,000 for herpes zoster,
which is comparable with incidences in some other
European countries [37,38]. However the incidence isFigure 5 Annual age-specific incidence of herpes zoster
infection from 2004 to 2008.
Table 5 Herpes zoster- related complication rates in Primary Care
(n = 3.371) Complication rates all ages Complication rates (%) per age group Corrected rate (%)
(n) (%) (95% CI) <60 60-64 >65 All (95% CI) >60 (95% CI)
Upper respiratory tract. ENT complications
Otitis media 203 6.02 (5.27-6.88) 6.0 5.2 6.3 1.77* (0.90-2.64) 3.55* (1.73-5.37)
Upper respiratory tract infection 350 10.38 (9.40-11.46) 8.9 12.3 14.7 5.55* (4.45-6.63) 7.96* (5.24-10.69)
Sum of complications 553 16.40 (15.19-17.69) 14.9 17.5 21.0 7.32 11.51
Total number of patientsa 501 14.86 (13.70-16.10)
Eye complications
Keratitis 13 0.39 (0.23-0.66) 0.3 0.0 0.8 0.39* (0.18-0.59) 0.64* (0.13-1.16)
Conjunctivitis 48 1.42 (1.08-1.88) 1.4 2.4 1.4 1.42* (1.02-1.82) 1.08* (0.14-2.01)
Problems Eyelids 96 2.85 (2.34-3.47) 2.5 4.7 3.6 2.83* (2.26-3.39) 3.76* (2.50-5.02)
Visus 18 0.53 (0.34-0.84) 0.4 0.9 0.8 0.53* (0.29-0.78) 0.86* (0.27-1.45)
Sum of complications 175 5.19 (4.49-5.99) 4.6 8.0 6.6 5.17 6.34
Total number of patientsa 147 4.36 (3.72-5.10)
Lower respiratory tract complications
Pneunomia 15 0.44 (0.27-0.73) 0.2 0.9 1.0 0.30* (0.07-0.53) 0.65 (−0.08-1.37)
Bronchitis 50 1.48 (1.13-1.95) 1.3 2.8 1.8 0.65* (0.21-1.08) 0.21 (−1.53-1.11)
Sum of complications 65 1.93 (1.52-2.45) 1.5 3.7 2.8 0.95 0.86
Total number of patientsa 64 1.90 (1.49 2.42)
Skin infectious/cutaneous complications
Phlegmon 13 0.39 (0.23-0.66) 0.4 0.0 0.6 0.29* (0.08-0.51) 0.22 (−0.30-0.73)
Pyoderma 13 0.39 (0.23-0.66) 0.4 0.0 0.4 0.30* (0.08-0.51) 0.11 (−0.36-0.58)
Abscess 30 0.89 (0.62-1.27) 0.8 1.9 0.8 0.57* (0.24-0.90) 0.86* (0.13-1.59)
Skin infection 32 0.95 (0.67-1.34) 0.9 0.0 1.4 0.77* (0.43-1.10) 0.86* (0.13-1.59)
Cellulitis 21 0.62 (0.41-0.95) 0.6 1.4 0.4 0.55* (0.28-0.82) 0.43 (−0.16-1.02)
Scar Tissue 46 1.36 (1.02-1.82) 1.3 0.5 1.9 0.57* (0.15-0.99) 0.97* (0.01-1.93)
Impetigo 112 3.32 (2.77-3.98) 3.9 1.4 1.8 2.65* (2.03-3.27) 1.61* (0.75-2.47)
Sum of complications 267 7.92 (7.06-8.88) 8.3 5.2 7.3 5.7 5.06
Total number of patientsa 234 6.94 (6.13 7.85)
PHN
PHN 195 5.78 (5.05 6.62) 3.4 8.0 13.1 5.78* (5.00-6.57) 11.92* (9.84-14.00)
Neurologic complications other than PHN
Syncope 27 0.80 (0.55-1.16) 0.5 0.5 1.8 0.38* (0.06-0.70) 1.50* (0.72-2.29)
Neuralgia (Trigeminal) 75 2.22 (1.78-2.78) 1.8 2.8 3.5 2.21* (1.71-2.71) 3.33* (2.18-4.48)
Meningitis 2 0.15 (0.02-0.22) 0.2 0.0 0.1 0.14 (−0.03-0.14) 0.11 (−0.10-0.32)
Ataxia (Cerebellitis) 1 0.03 (0.01-0.17) 0.04 0.0 0.0 0.03 (−0.03-0.09) 0.00
Movement and stability dysfunct. 6 0.18 (0.08-0.39) 0.1 0.0 0.6 0.18* (0.04-0.32) 0.43* (0.01-0.85)
Vertigo 97 2.88 (2.36-3.50) 2.3 1.9 5.0 2.36* (1.79-2.94) 3.12* (1.64-4.59)
Facial palsy 33 0.98 (0.70-1.37) 0.8 0.0 1.8 0.98* (0.65-1.31) 1.40* (0.64-2.15)
Coma 1 0.03 (0.01-0.17) 0.0 0.0 0.0 0.03 (−0.03-0.09) 0.00
Pain face 24 0.71 (0.48-1.06) 0.5 0.9 1.3 0.69* (0.41-0.97) 1.18* (0.49-1.88)
Sum of complications 266 7.89 (7.03-8.85) 6.24 6.1 14.1 7.00 11.07
Total number of patientsa 258 7.65 (6.80-8.60)
Gastrointestinal tract complications
Stomatitis 9 0.27 (0.14-0.51) 0.2 0.5 0.3 0.24* (0.06-0.41) 0.43* (0.01-0.85)
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Table 5 Herpes zoster- related complication rates in Primary Care (Continued)
Gastroenteritis 52 1.54 (1.18-2.02) 1.2 3.3 2.2 0.63* (0.18-1.07) 1.18 (−0.05-2.42)
Pancreatitis 10 0.30 (0.16-0.55) 0.1 1.9 0.6 0.25* (0.07-0.44) 0.86* (0.27-1.45)
Sum of complications 71 2.11 (1.67-2.65) 1.5 5.7 3.1 1.12 2.47
Total number of patientsa 66 1.96 (1.54-2.48)
Complications due to (systemic) bacterial infections
Sepsis 1 0.03 (0.01-0.17) 0.04 0.0 0.0 0.02 (−0.04-0.08) 0.00
Pyogen arthritis 3 0.09 (0.03-0.26) 0.08 0.5 0.0 0.09 (−0.01-0.19) 0.11 (−0.10-0.32)
Sum of complications 4 0.12 (0.05-0.30) 0.1 0.5 0.0 0.11 0.11
Total number of patientsa 4 0.12 (0.05-0.30)
Symptoms
Coughing 241 7.15 (6.33-8.07) 6.1 7.5 10.7 3.29* (2.36-4.22) 6.88* (4.66-9.11)
Snivelling 26 0.77 (0.53-1.13) 0.7 0.5 1.0 0.46* (0.15-0.77) 0.54 (−0.16-1.23)
Fever 703 20.85 (19.52-22.26) 20.5 20.8 22.0 12.41* (10.95-13.85) 16.23* (13.21-19.25)
Fatigue 148 4.39 (3.75-5.14) 4.2 1.9 5.8 2.80* (2.08-3.52) 3.23* (1.60-4.85)
Emesis/Vomiting 121 3.59 (3.01-4.27) 3.0 3.3 5.6 2.15* (1.49-2.81) 4.30* (2.79-5.81)
Pruritis/Itching 1.005 29.81 (28.29-31.38) 31.7 17.9 26.8 22.64* (21.03-24.23) 17.20* (13.95-20.46)
Skin rash/Exanthema 400 11.87 (10.82-13.00) 11.2 13.2 13.6 11.00* (9.89-12.09) 12.78* (10.52-15.05)
Dehydration/Diarreah 106 3.14 (2.61-3.79) 2.6 2.4 5.3 1.58* (1.03-2.27) 3.76* (2.29-5.23)
aThe total number of patients may be less than the total sum of complications because some patients had more than one complication in this group.
* = p< 0.05.
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lands [1] and in England and Wales [39]. Associated
morbidity is mostly age dependent; it increased during
life-time. For example the incidence rate of PHN, VZV
most registrated complication, is low (3.4%) in patient
younger than 60 year and 13.9% in patient older than
65 years of age. It is believed that herpes zoster is gener-
ally associated with normal aging and with anything that
causes reduced immunocompetence [40].
The estimated complication rate was 32.9%, most
complications corresponded to the affected dermatome,
for example trigeminal neuralgia. More than two-third
of the cases who consulted a GP for herpes zoster
received medication. Almost one-quarter of all herpes
zoster patients were treated with antiviral therapy, which
is comparable to the 22.5% found in a Dutch GP-survey
[41].Strength and limitations
The scope of this study was limited to patients with vari-
cella and herpes zoster seeking help from a general prac-
titioner. In particular, the study relies on what GPs
document with ICPC-coding and in free text which may
not be totally complete. Even though the database was
very elaborate, the data included for hospital care (refer-
rals/discharge) was limited to the referrals recorded by
the attending GP and might underestimate the occur-
rence of more serious complications.Nevertheless, false negative and positive misclassifica-
tion may have occurred. We relied on GP diagnoses
which are usually based on the recording of symptoms
without objective diagnostic evidence. Moreover, we may
have missed VZV cases that did not fall within the range
of search terms included in our study although all syno-
nyms and lay names were generated by Dutch experts.
However, due to our elaborate search the underestima-
tion following this possible bias is expected to be very
small. Misclassification can also appear by the occur-
rence of VZV associated complications. Because most
potential VZV associated complications are not compli-
cations caused only specific by VZV, we can not con-
sider all relationships within our chosen time range
equally plausible in a causal sense. For instance, it is not
clear if the herpes zoster related deaths were caused by
herpes zoster or if herpes zoster was a reactivated be-
cause of reduced immunocompetence of the patients.
To increase plausibility of causal associations the com-
plication rates were corrected for a baseline rate by
using a reference disease verruca (warts). Verruca is, like
herpes zoster and varicella, caused by a virus and affects
the skin. A possible limitation of our study is that some
of the patients might already have been treated before
2004 or continued treatment in 2009. Therefore we
might have an underestimation of cases and health care
resource use. The projections of incidences on the gen-
eral Dutch population are based on an assumption of
demographic generalisability of the study population.
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ethnicity and socio-economic factors may explain the
observed difference in incidence rates. More likely, how-
ever, would be that the differences with the national
registration (NIVEL) are related to differences in exact
case definitions and our extensive validation process. Be-
cause the age distribution in our database slightly dif-
fered from the age distribution of the Dutch population
we determined standardized incidence estimates of vari-
cella and herpes zoster when extrapolating our results to
the Dutch population.
The strength of this study lies in the elaborate infor-
mation available in the research database from the mu-
nicipality of Almere which combines GP data (incl. free
text in the medical record notes), hospital data and phar-
macy data to analyze epidemiologic characteristics and
disease burden of varicella and herpes zoster in the
Netherlands. Another strength of this study lies in the
use of both coded and non-coded information; this way
our study is based on a broader case definition enabling
us to avoid possible underestimation by missing cases
only reported in free text field. The incidence estima-
tions were based on a sensitive and detailed search algo-
rithm (including typing errors and misspellings)
followed by a review of the full-text medical records of
the selected patients. In combination, this ZGA data
enables us to have an extensive view of the occurrence
of VZV and it’s complications in the GP practices.
Conclusion
This study has provided important epidemiological back-
ground data on VZV-infections in the Netherlands, which
is useful for clinical practice and decisions makers.
Present study shows the true burden of disease due to a
primary or recurrent VZV infection based on coded and
non coded information. Though the proportion of people
that undergo complications following VZV infections is
small, almost the entire population gets primary VZV-
infection. Therefore, the absolute number of people with a
complication for varicella is high. Our study shows that the
occurrence of complications is not age-dependant but var-
ies per complication. This challenges the common belief
that (severe) complications only occur when getting vari-
cella at an older age. Frequency of reactivation of the virus
occurs with advancing age. Associated morbidity increases
also during life-time. Although the risk of suffering herpes
zoster infection over the course of life-time has previously
been estimated at 20 at 30% [5], the health care resource
uses are as high as for varicella.
It is important to know that when incidences of VZV-
infections and their associated complications are esti-
mated based on coded information only, one should be
aware of a gross underestimation of the incidences. Our
analysis may have important implications for commonpractice concerning VZV patients. Additionally policy-
makers may take our results into consideration when dis-
cussing the prevention of VZV-associated complications.
More insights regarding medical complications resulting
into hospitalization and intramural treatment are neces-
sary to get a better understanding of disease burden.
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